Organisation paid for research Program year 2025 Source: CMS Open Payments

Coastal Neurology

Neither a doctor nor a teaching hospital

Research payments

$732,086

218 payments

Through program year 2025, Coastal Neurology is reported as receiving $732,086 in research payments, across 218 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $58,427 9
2024 Research $38,615 4
2023 Research $25,563 13
2022 Research $11,116 5
2021 Research $28,328 8
2020 Research $314,250 37
2019 Research $255,786 142

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $623,817 185 payments
  2. AbbVie, Inc. $37,410 8 payments
  3. Biogen, Inc. $36,498 1 payment
  4. Novo Nordisk AS $28,046 20 payments
  5. Novartis Pharmaceuticals Corporation $6,315 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $309,150 148 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $265,992 21 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease $44,175 15 payments
  4. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $36,498 1 payment
  5. Nn6535-4725 $28,046 20 payments
  6. A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinsons Disease Patients $18,060 5 payments
  7. Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinsons Disease $10,750 1 payment
  8. A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinsons Disease Patients $8,493 1 payment
  9. Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $5,547 3 payments
  10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia $4,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record